Drugs / FENOBAM ANHYDROUS
FENOBAM ANHYDROUS
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01981395 | Jan 2014 → Feb 2015 | allesthesia | Laura Cavallone | Completed | No outcome recorded |
| Phase 1 | NCT01806415 | May 2013 → Mar 2014 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00637221 | Mar → Apr 2008 | fragile X syndrome | Neuropharm | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FENOBAM ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL239800 ↗ |
| Known as | Fenobam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01806415 ↗ |
| Known as | MCN-3377-98 | ChEMBL registry synonym — accepted as the source's own label CHEMBL239800 ↗ |
| Known as | NPL-2009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00637221 ↗ |
| Action | Inhibit | “mGlu5 Antagonist Fenobam” NCT01806415 ↗ |
| Modality | Small molecule | — CHEMBL239800 ↗ |
| Route | Oral | “oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)” NCT01806415 ↗ |